👤 Serina Huang

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
1370
Articles
1004
Name variants
Also published as: Ai-Chun Huang, Ai-long Huang, Aijie Huang, Ailong Huang, Aimin Huang, Alden Y Huang, An-Fang Huang, Annie Huang, Aohuan Huang, Ariane Huang, Baihai Huang, Baisong Huang, Bao-Hua Huang, Bao-Yi Huang, Baoqin Huang, Baoying Huang, Benjamin J Huang, Benlin Huang, Bevan E Huang, Bi Huang, Biao Huang, Bin Huang, Binfang Huang, Bing Huang, Bingcang Huang, Bingkun Huang, Bizhi Huang, Bo Huang, Bo-Shih Huang, Bor-Ren Huang, Bowen Huang, Boyue Huang, C Y Huang, Caihong Huang, Caiyun Huang, Can Huang, Canhua Huang, Caoxin Huang, Cathelin Huang, Catherine Huang, Chang Ming Huang, Chang X Huang, Chang-Jen Huang, Changjiang Huang, Chao Huang, Chao Wei Huang, Chao-Wei Huang, Chao-Yuan Huang, Chaolin Huang, Chaoqun Huang, Chaowang Huang, Chaoyang Huang, Chen Huang, Chen-Na Huang, Chen-Ping Huang, Cheng Huang, Chengcheng Huang, Chengrui Huang, Chenshen Huang, Chenxiao Huang, Chi-Cheng Huang, Chi-Shuan Huang, Chia-Chang Huang, Chia-Wei Huang, Chieh-Cheng Huang, Chieh-Liang Huang, Chien-Hsun Huang, Chih-Chun Huang, Chih-Hsiang Huang, Chih-Jen Huang, Chih-Ting Huang, Chih-Yang Huang, Chin-Chang Huang, Chin-Chou Huang, Ching-Shan Huang, Ching-Shin Huang, Ching-Tang Huang, Ching-Wei Huang, Chiu-Ju Huang, Chiu-Jung Huang, Chiun-Sheng Huang, Chong Huang, Chongbiao Huang, Christine S Huang, Chuan Huang, Chuanbing Huang, Chuanhong Huang, Chuanjiang Huang, Chuanjun Huang, Chuansheng Huang, Chuiguo Huang, Chun Huang, Chun-Mei Huang, Chun-Yao Huang, Chun-Yin Huang, Chunfan Huang, Chung-Hsiung Huang, Chunhong Huang, Chunjian Huang, Chunkai Huang, Chunlan Huang, Chunling Huang, Chunshuai Huang, Chunxia Huang, Chunyao Huang, Chunyi Huang, Chunying Huang, Chunyu Huang, Chuxin Huang, Chuying Huang, Congcong Huang, Cuiyu Huang, Da Huang, Dajun Huang, Dan Huang, Dane Huang, Danqing Huang, Dantong Huang, David Huang, David J Huang, De Huang, De-Jun Huang, Dejia Huang, Dengjun Huang, Dianhua Huang, Dishu Huang, Dong Huang, Donglan Huang, Dongmei Huang, Dongni Huang, Dongqin Huang, Dongqing Huang, Dongsheng Huang, Dongyu Huang, Du-Juan Huang, Emily C Huang, Enhao Huang, Enping Huang, Eric Huang, Erya Huang, F Huang, Fan Huang, Fang Huang, Fang-Ling Huang, Fangling Huang, Fei Huang, Fei Wan Huang, Feiruo Huang, Feiteng Huang, Feizhou Huang, Feng Huang, Fengxian Huang, Fengyu Huang, Franklin W Huang, Fu-Chen Huang, Fu-Mei Huang, Fubiao Huang, Fude Huang, Fuhao Huang, Furong Huang, G Huang, Gairong Huang, Gang Huang, Gao-Zhong Huang, Gaoxingyu Huang, Ge Huang, Guang-Jian Huang, Guang-Yun Huang, Guangjian Huang, Guangming Huang, Guangqian Huang, Guangrui Huang, Guanhong Huang, Guanling Huang, Guanning Huang, Guanqun Huang, Guanrong Huang, Guicheng Huang, Guodong Huang, Guohong Huang, Guoping Huang, Guoqian Huang, Guowei Huang, Guoxing Huang, Guoying Huang, Guoyong Huang, Guoyuan Huang, H Huang, H S Huang, Hai Huang, Haigang Huang, Haihong Huang, Hailin Huang, Haimiao Huang, Haixin Huang, Haiyan Huang, Han-Chang Huang, Hanxia Huang, Hao Huang, Hao-Fei Huang, Haobo Huang, Haochu Huang, Haomin Huang, Haoyu Huang, Haoyue Huang, Haozhang Huang, Haozhong Huang, He Huang, Hefeng Huang, Heguang Huang, Helen Huang, Heming Huang, Hengbin Huang, Heqing Huang, Hete Huang, Hong Huang, Hongbiao Huang, Hongcan Huang, Hongda Huang, Hongfei Huang, Hongfeng Huang, Honghui Huang, Hongou Huang, Hongqiang Huang, Hongyan Huang, Hongyang Huang, Hongyi Huang, Hongying Huang, Hongyu Huang, Hongyun Huang, Hsi-Yuan Huang, Hsien-Da Huang, Hsing-Yen Huang, Hsu Chih Huang, Hsuan-Cheng Huang, Hsuan-Ying Huang, Hu Huang, Hua Huang, Huafei Huang, Huaju Huang, Huan Huang, Huanhuan Huang, Huanliang Huang, Huapin Huang, Huashan Huang, Huayun Huang, Hui Huang, Hui-Huang Huang, Hui-Kuang Huang, Hui-Yu Huang, Huibin Huang, Huifen Huang, Huiling Huang, Huimin Huang, Huina Huang, Huiqiao Huang, Huixian Huang, Huixin Huang, Huiyan Huang, Huiyu Huang, Huizhe Huang, Huizhen Huang, Hy Huang, I-Chieh Huang, J V Huang, Janice J Huang, Jasmin Huang, Jeffrey K Huang, Jia Huang, Jia-Jia Huang, Jiaan Huang, Jiahui Huang, Jiajin Huang, Jiajun Huang, Jian Huang, Jian-Dong Huang, Jiana Huang, Jianbiao Huang, Jianbing Huang, Jianfang Huang, Jianfeng Huang, Jiangfeng Huang, Jiangtao Huang, Jiangwei Huang, Jianhua Huang, Jianlu Huang, Jianmin Huang, Jianming Huang, Jiansheng Huang, Jianzhen Huang, Jiao-Qian Huang, Jiaoti Huang, Jiaotian Huang, Jiaqi Huang, Jiawen Huang, Jiaxing Huang, Jiayu Huang, Jiayue Huang, Jie Huang, Jie Qi Huang, Jiechun Huang, Jieli Huang, Jieling Huang, Jieping Huang, Jin Huang, Jin-Di Huang, Jin-Feng Huang, Jin-Hong Huang, Jin-Yan Huang, Jinbao Huang, Jinfang Huang, Jing Huang, Jing-Fei Huang, Jingang Huang, Jinghan Huang, Jingjing Huang, Jingkun Huang, Jinglong Huang, Jingtao Huang, Jingxian Huang, Jingyong Huang, Jingyuan Huang, Jingyue Huang, Jinhua Huang, Jinling Huang, Jinlu Huang, Jinshu Huang, Jinxing Huang, Jinyan Huang, Jinzhou Huang, Jiuhong Huang, Jiyu Huang, Ju Huang, Juan Huang, Jucun Huang, Jun Huang, Jun-Hua Huang, Jun-You Huang, Junhao Huang, Junhua Huang, Junjie Huang, Junming Huang, Junning Huang, Junqi Huang, Junwen Huang, Junyuan Huang, Junyun Huang, Juxiang Huang, K Huang, K N Huang, Kai Huang, Kaipeng Huang, Kang Huang, Kangbo Huang, Kate Huang, Katherine Huang, Ke Huang, Ke-Ke Huang, Ke-Pu Huang, Kevin Huang, Kevin Y Huang, Kuan-Chun Huang, Kui-Yuan Huang, Kuiyuan Huang, Kun Huang, Kuo-Hsiang Huang, Kuo-Hung Huang, L Huang, L-B Huang, Laiqiang Huang, Lan Huang, Lanlan Huang, Lei Huang, Leijuan Huang, Li Huang, Li-Hao Huang, Li-Jiang Huang, Li-Juan Huang, Li-Jun Huang, Li-Ping Huang, Li-Rung Huang, Li-Wei Huang, Li-Yun Huang, Lian Huang, Liang Huang, Liang-Yu Huang, Liangchong Huang, Lianggui Huang, Libin Huang, Lige Huang, Lihua Huang, Lijia Huang, Lijiang Huang, Lijuan Huang, Lijun Huang, Lili Huang, Limin Huang, Liming Huang, Lin Huang, Linchen Huang, Ling Huang, Ling-Chun Huang, Ling-Jin Huang, Lingling Huang, Lining Huang, Linjing Huang, Linsheng Huang, Linxue Huang, Linyuan Huang, Liping Huang, Liqiong Huang, Lixia Huang, Lixiang Huang, Lixuan Huang, Lixue Huang, Lizhen Huang, Longfei Huang, Lu Huang, Lu-Jie Huang, Lu-Qi Huang, Luanluan Huang, Luqi Huang, Luyang Huang, Luyao Huang, Lvzhen Huang, M C Huang, Man Huang, Manning Y Huang, Manyun Huang, Mao-Mao Huang, Mei Huang, Meihua Huang, Meina Huang, Meixiang Huang, Melissa Y Huang, Meng-Chuan Huang, Meng-Fan Huang, Meng-Na Huang, MengQian Huang, Menghao Huang, Mengjie Huang, Mengjun Huang, Mengnan Huang, Mengting Huang, Mengzhen Huang, Mia L Huang, Miao Huang, Min Huang, Ming-Lu Huang, Ming-Shyan Huang, Mingjian Huang, Mingjun Huang, Minglei Huang, Mingrui Huang, Mingwei Huang, Mingxuan Huang, Mingyu Huang, Mingyuan Huang, Minjun Huang, Minqi Huang, Minxuan Huang, Minyuan Huang, N Huang, Na Huang, Nian Huang, Nianyuan Huang, Ning-Na Huang, Ning-Ping Huang, Ninghao Huang, Nongyu Huang, Pan Huang, Pang-Shuo Huang, Paul L Huang, Pei Huang, Pei-Chi Huang, Pei-Ying Huang, Peiying Huang, Peng Huang, Peng-Fei Huang, Pengyu Huang, Piao-Piao Huang, Piaopiao Huang, Pin-Rui Huang, Ping Huang, Pingping Huang, Pintong Huang, Po-Hsun Huang, Po-Jung Huang, Poyao Huang, Qi Huang, Qi-Tao Huang, Qian Huang, Qiang Huang, Qianqian Huang, Qiaobing Huang, Qibin Huang, Qidi Huang, Qin Huang, Qing Huang, Qing-yong Huang, Qingjiang Huang, Qingke Huang, Qingling Huang, Qingqing Huang, Qingsong Huang, Qingxia Huang, Qingxing Huang, Qingyu Huang, Qingzhi Huang, Qinlou Huang, Qiong Huang, Qiubo Huang, Qiumin Huang, Qiuming Huang, Qiuru Huang, Qiuyin Huang, Qiuyue Huang, Qizhen Huang, Quanfang Huang, Qun Huang, R H Huang, R Stephanie Huang, Rae-Chi Huang, Ran Huang, Renbin Huang, Renhua Huang, Renli Huang, Richard Huang, Richard S P Huang, Riqing Huang, Ritai Huang, Robert J Huang, Rong Huang, Rong Stephanie Huang, Ronghua Huang, Ronghui Huang, Rongjie Huang, Rongrong Huang, Rongxiang Huang, Ru-Ting Huang, Ruby Yun-Ju Huang, Rui Huang, Ruihua Huang, Ruijin Huang, Ruina Huang, Ruiyan Huang, Ruizhen Huang, Runyue Huang, Ruo-Hui Huang, S Huang, S Y Huang, S Z Huang, Saisai Huang, San-Yuan Huang, See-Chang Huang, Sen Huang, Shan Huang, Shang-Ming Huang, Shanhe Huang, Shanshan Huang, Shaojun Huang, Shaoxin Huang, Shaoze Huang, Shau Ku Huang, Shau-Ku Huang, Shenan Huang, Sheng-He Huang, Shengfeng Huang, Shengjie Huang, Shengnan Huang, Shengyan Huang, Shengyun Huang, Shi-Feng Huang, Shi-Shi Huang, Shi-Ying Huang, Shiang-Suo Huang, Shichao Huang, Shih-Chiang Huang, Shih-Wei Huang, Shih-Yi Huang, Shihao Huang, Shijing Huang, Shilu Huang, Shixia Huang, Shiya Huang, Shiying Huang, Shiyun Huang, Shoucheng Huang, Shu Huang, Shu-Pang Huang, Shu-Pin Huang, Shu-Qiong Huang, Shu-Wei Huang, Shu-Yi Huang, Shu-ying Huang, Shuai Huang, Shuang Huang, Shungen Huang, Shuo Huang, Shushu Huang, Shutong Huang, Shuwen Huang, Si-Yang Huang, Sidong Huang, Sihua Huang, Sijia Huang, Sinchun Huang, Sisi Huang, Sixiu Huang, Song Bin Huang, Song-Mei Huang, Songmei Huang, Songming Huang, Songqian Huang, Steven Huang, Steven Kuan-Hua Huang, Suli Huang, Sung-Ying Huang, Susan M Huang, Suwen Huang, Taiqi Huang, Tang-Hsiu Huang, Tao Huang, Te-Hsuan Huang, Tengda Huang, Tengfei Huang, Tian Hao Huang, Tianhao Huang, Tianpu Huang, Tiantian Huang, Tieqiu Huang, Tim H Huang, Ting Huang, Tinghua Huang, Tingping Huang, Tingqin Huang, Tingting Huang, Tingxuan Huang, Tingyun Huang, Tong Huang, Tongsheng Huang, Tongtong Huang, Tony T Huang, Tse-Shun Huang, Tseng-Yu Huang, Tsung-Wei Huang, Tzu-Rung Huang, Wan-Ping Huang, Way-Ren Huang, Wei Huang, Wei-Chi Huang, Weibin Huang, Weicheng Huang, Weifeng Huang, Weihua Huang, Weijun Huang, Weiqi Huang, Weisu Huang, Weiwei Huang, Weixue Huang, Weizhen Huang, Wen Huang, Wen-yu Huang, Wenbin Huang, Wenda Huang, Wenfang Huang, Wenfeng Huang, Wenhua Huang, Wenji Huang, Wenjie Huang, Wenjun Huang, Wenqiao Huang, Wenqing Huang, Wenqiong Huang, Wenshan Huang, Wentao Huang, Wenxin Huang, Wenya Huang, Wenying Huang, Wunan Huang, Wuqing Huang, X F Huang, X Huang, Xi Huang, Xian-sheng HUANG, Xiang Huang, Xianghua Huang, Xianglong Huang, Xiangming Huang, Xianping Huang, Xianqing Huang, Xiansheng Huang, Xianwei Huang, Xianxi Huang, Xianxian Huang, Xianying Huang, Xianzhang Huang, Xiao Huang, Xiao-Fang Huang, Xiao-Fei Huang, Xiao-Ming Huang, Xiao-Song Huang, Xiao-Yan Huang, Xiao-Yong Huang, Xiao-Yu Huang, XiaoFang Huang, Xiaochun Huang, Xiaofei Huang, Xiaofeng Huang, Xiaohong Huang, Xiaohua Huang, Xiaojie Huang, Xiaojing Huang, Xiaojuan Huang, Xiaolan Huang, Xiaoli Huang, Xiaolin Huang, Xiaoman Huang, Xiaomin Huang, Xiaoqing Huang, Xiaoshuai Huang, Xiaowen Huang, Xiaowu Huang, Xiaoxia Huang, Xiaoyan Huang, Xiaoying Huang, Xiaoyu Huang, Xiaoyuan Huang, Xiaoyun Huang, Xiaozhun Huang, Xiayang Huang, Xichang Huang, Xie-Lin Huang, Xin Huang, Xin-Di Huang, Xinen Huang, Xinfeng Huang, Xingguo Huang, Xingming Huang, Xingqin Huang, Xingru Huang, Xingxu Huang, Xingya Huang, Xingzhen Huang, Xinwen Huang, Xinyi Huang, Xinying Huang, Xinyue Huang, Xinzhu Huang, Xiongfeng Huang, Xionggao Huang, Xiuju Huang, Xiuyun Huang, Xiuzhen Huang, Xiwen Huang, Xu Huang, Xu-Feng Huang, Xuan Huang, Xuanzhang Huang, Xucong Huang, Xudong Huang, Xue-Ying Huang, Xue-shuang Huang, Xuehong Huang, Xuejie Huang, Xuejing Huang, Xuejun Huang, Xuemei Huang, Xueming Huang, Xueqi Huang, Xuewei Huang, Xuezhe Huang, Xuhui Huang, Xuliang Huang, Xun Huang, Xuxiong Huang, Y Huang, Y Joyce Huang, Y S Huang, Ya-Chih Huang, Ya-Dong Huang, Ya-Fang Huang, Ya-Ru Huang, Yabo Huang, Yadong Huang, Yafang Huang, Yajiao Huang, Yajuan Huang, Yali Huang, Yamei Huang, Yan Huang, Yan-Lin Huang, Yan-Qing Huang, Yan-Ting Huang, Yang Huang, Yang Zhong Huang, Yangqing Huang, Yangyang Huang, Yanhao Huang, Yani Huang, Yanjun Huang, Yanlong Huang, Yanna Huang, Yanping Huang, Yanqin Huang, Yanqing Huang, Yanqun Huang, Yanru Huang, Yanshan Huang, Yansheng Huang, Yanxia Huang, Yanyan Huang, Yanyao Huang, Yao Huang, Yao-Kuang Huang, Yaowei Huang, Yatian Huang, Yating Huang, Ye Huang, Yechao Huang, Yen-Chu Huang, Yen-Ning Huang, Yen-Tsung Huang, Yeqing Huang, Yewei Huang, Yi Huang, Yi-Chun Huang, Yi-Jan Huang, Yi-Jia Huang, Yi-Wen Huang, Yi-ping Huang, Yichao Huang, Yichuan Huang, Yicong Huang, Yifan Huang, Yihao Huang, Yiheng Huang, Yihong Huang, Yikeng Huang, Yilin Huang, Yin Huang, Yin-Tsen Huang, Ying Huang, Ying-Hsuan Huang, Ying-Jung Huang, Ying-Zhi Huang, Yinghua Huang, Yingying Huang, Yingzhen Huang, Yingzhi Huang, Yiping Huang, Yiquan Huang, Yishan Huang, Yiwei Huang, Yixian Huang, Yizhou Huang, Yong Huang, Yong-Fu Huang, Yongbiao Huang, Yongcan Huang, Yongjie Huang, Yongqi Huang, Yongsheng Huang, Yongtong Huang, Yongye Huang, Yongyi Huang, Yongzhen Huang, Youheng Huang, Youyang Huang, Yu Huang, Yu-Ching Huang, Yu-Chu Huang, Yu-Chuen Huang, Yu-Chyi Huang, Yu-Fang Huang, Yu-Han Huang, Yu-Jie Huang, Yu-Lei Huang, Yu-Ren Huang, Yu-Shu Huang, Yu-Ting Huang, Yuan Huang, Yuan-Lan Huang, Yuan-Li Huang, Yuan-Lu Huang, Yuancheng Huang, Yuanpeng Huang, Yuanshuai Huang, Yuanyu Huang, Yuanyuan Huang, Yue Huang, Yue-Hua Huang, Yuedi Huang, Yueh-Hsiang Huang, Yuehong Huang, Yuejun Huang, Yueye Huang, Yuezhen Huang, Yufang Huang, Yufen Huang, Yuguang Huang, Yuh-Chin T Huang, Yuhong Huang, Yuhua Huang, Yuhui Huang, Yujia Huang, Yujie Huang, Yulin Huang, Yumei Huang, Yumeng Huang, Yun Huang, Yun-Juan Huang, Yunchao Huang, Yung-Hsin Huang, Yung-Yu Huang, Yunmao Huang, Yunpeng Huang, Yunru Huang, Yunyan Huang, Yuping Huang, Yuqi Huang, Yuqiang Huang, Yuqiong Huang, Yusi Huang, Yutang Huang, Yuting Huang, Yutong Huang, Yuxian Huang, Yuxin Huang, Yuxuan Huang, Yuyang Huang, Yuying Huang, Z Huang, Z Z Huang, Z-Y Huang, Zebin Huang, Zebo Huang, Zehua Huang, Zeling Huang, Zengwen Huang, Zhang Huang, Zhao Huang, Zhaoxia Huang, Zhe Huang, Zhen Huang, Zhenfei Huang, Zheng Huang, Zheng-Xiang Huang, Zhengwei Huang, Zhengxian Huang, Zhengxiang Huang, Zhengyang Huang, Zhenlin Huang, Zhenrui Huang, Zhenyao Huang, Zhenyi Huang, Zhi Huang, Zhi-Ming Huang, Zhi-Qiang Huang, Zhi-Xin Huang, Zhi-xiang Huang, Zhican Huang, Zhicong Huang, Zhifang Huang, Zhifeng Huang, Zhigang Huang, Zhihong Huang, Zhilin Huang, Zhilong Huang, Zhipeng Huang, Zhiping Huang, Zhiqi Huang, Zhiqiang Huang, Zhiqin Huang, Zhiqing Huang, Zhitong Huang, Zhiwei Huang, Zhixiang Huang, Zhiying Huang, Zhiyong Huang, Zhiyu Huang, Zhongbin Huang, Zhongcheng Huang, Zhongfeng Huang, Zhonglu Huang, Zhouyang Huang, Zi-Xin Huang, Zi-Ye Huang, Zicheng Huang, Zichong Huang, Zihan Huang, Zihao Huang, Ziheng Huang, Ziling Huang, Zini Huang, Zirui Huang, Zizhan Huang, Zongjian Huang, Zongliang Huang, Zunnan Huang, Zuotian Huang, Zuxian Huang, Zuyi Huang
articles
Guoqing Wan, Jiang Zhu, Xuefeng Gu +7 more · 2020 · British journal of cancer · Nature · added 2026-04-24
Human Schlafen 5 (SLFN5) has been reported to inhibit or promote cell invasion in tumours depending on their origin. However, its role in breast cancer (BRCA) is undetermined. Differential expression Show more
Human Schlafen 5 (SLFN5) has been reported to inhibit or promote cell invasion in tumours depending on their origin. However, its role in breast cancer (BRCA) is undetermined. Differential expression analyses using The Cancer Genome Atlas (TCGA) data, clinical samples and cell lines were performed. Lentiviral knockdown and overexpression experiments were performed to detect changes in cell morphology, molecular markers and invasion. Chromatin immunoprecipitation-sequencing (ChIP-Seq) and luciferase reporter assays were performed to detect the SLFN5-binding motif. TCGA, clinical samples and cell lines showed that SLFN5 expression was negatively correlated with BRCA metastasis. SLFN5 knockdown induced epithelial-mesenchymal transition (EMT) and enhanced invasion in BRCA cell lines. However, overexpression triggered mesenchymal-epithelial transition (MET). SLFN5 inhibited the expression of ZEB1 but not ZEB2, SNAI1, SNAI2, TWIST1 or TWIST2. Knockdown and overexpression of ZEB1 indicated that it was a mediator of the SLFN5-governed phenotype and invasion changes. Moreover, SLFN5 inhibited ZEB1 transcription by directly binding to the SLFN5-binding motif on the ZEB1 promoter, but a SLFN5 C-terminal deletion mutant did not. SLFN5 regulates reversible epithelial and mesenchymal transitions, and inhibits BRCA metastasis by suppression of ZEB1 transcription, suggesting that SLFN5 could be a potential target for BRCA therapy. Show less
no PDF DOI: 10.1038/s41416-020-0873-z
SNAI1
Cheng-Chan Yu, Sung-Ying Huang, Shu-Fang Chang +2 more · 2020 · Molecules (Basel, Switzerland) · MDPI · added 2026-04-24
Hepatocellular carcinoma (HCC) is the most common type of liver cancer worldwide. Regorafenib is a multi-kinase inhibitor and the second-line treatment for HCC. Since the PI3K/Akt/mTOR signaling pathw Show more
Hepatocellular carcinoma (HCC) is the most common type of liver cancer worldwide. Regorafenib is a multi-kinase inhibitor and the second-line treatment for HCC. Since the PI3K/Akt/mTOR signaling pathway is dysregulated in HCC, we evaluated the therapeutic effects of regorafenib combined with a dual PI3K/mTOR inhibitor BEZ235 in the human HCC cell lines ( Show less
no PDF DOI: 10.3390/molecules25102454
SNAI1
Xiao-Yong Huang, Peng-Fei Zhang, Chuan-Yuan Wei +9 more · 2020 · Molecular cancer · BioMed Central · added 2026-04-24
Amplification of chromosome 7q21-7q31 is associated with tumor recurrence and multidrug resistance, and several genes in this region are powerful drivers of hepatocellular carcinoma (HCC). We aimed to Show more
Amplification of chromosome 7q21-7q31 is associated with tumor recurrence and multidrug resistance, and several genes in this region are powerful drivers of hepatocellular carcinoma (HCC). We aimed to investigate the key circular RNAs (circRNAs) in this region that regulate the initiation and development of HCC. We used qRT-PCR to assess the expression of 43 putative circRNAs in this chromosomal region in human HCC and matched nontumor tissues. In addition, we used cultured HCC cells to modify circRNA expression and assessed the effects in several cell-based assays as well as gene expression analyses via RNA-seq. Modified cells were implanted into immunocompetent mice to assess the effects on tumor development. We performed additional experiments to determine the mechanism of action of these effects. circMET (hsa_circ₀₀₈₂₀₀₂₎ was overexpressed in HCC tumors, and circMET expression was associated with survival and recurrence in HCC patients. By modifying the expression of circMET in HCC cells in vitro, we found that circMET overexpression promoted HCC development by inducing an epithelial to mesenchymal transition and enhancing the immunosuppressive tumor microenvironment. Mechanistically, circMET induced this microenvironment through the miR-30-5p/Snail/ dipeptidyl peptidase 4(DPP4)/CXCL10 axis. In addition, the combination of the DPP4 inhibitor sitagliptin and anti-PD1 antibody improved antitumor immunity in immunocompetent mice. Clinically, HCC tissues from diabetic patients receiving sitagliptin showed higher CD8 circMET is an onco-circRNA that induces HCC development and immune tolerance via the Snail/DPP4/CXCL10 axis. Furthermore, sitagliptin may enhance the efficacy of anti-PD1 therapy in a subgroup of patients with HCC. Show less
no PDF DOI: 10.1186/s12943-020-01213-6
SNAI1
Vignesh Sundararajan, Ming Tan, Tuan Zea Tan +4 more · 2020 · Cancers · MDPI · added 2026-04-24
Over two decades of research on cancer-associated epithelial-mesenchymal transition (EMT) led us to ascertain the occurrence of transitional intermediate states (collectively referred to as the EMT sp Show more
Over two decades of research on cancer-associated epithelial-mesenchymal transition (EMT) led us to ascertain the occurrence of transitional intermediate states (collectively referred to as the EMT spectrum). Among the molecular factors that drive EMT, SNAI1 plays an indispensable role in regulating other core transcription factors, and this regulation is highly context-dependent. However, molecular investigation on this context-dependent regulation is still lacking. Using two ovarian cancer cell lines, we show that SNAI1 regulation on other core EMT-TFs switches from a repressive control in highly epithelial cells to an activation signaling in intermediate epithelial cells. Upon further scrutiny, we identify that the expression of early epithelial genes Show less
no PDF DOI: 10.3390/cancers12051140
SNAI1
Catherine L Carmichael, Jueqiong Wang, Thao Nguyen +34 more · 2020 · Blood · added 2026-04-24
Modulators of epithelial-to-mesenchymal transition (EMT) have recently emerged as novel players in the field of leukemia biology. The mechanisms by which EMT modulators contribute to leukemia pathogen Show more
Modulators of epithelial-to-mesenchymal transition (EMT) have recently emerged as novel players in the field of leukemia biology. The mechanisms by which EMT modulators contribute to leukemia pathogenesis, however, remain to be elucidated. Here we show that overexpression of SNAI1, a key modulator of EMT, is a pathologically relevant event in human acute myeloid leukemia (AML) that contributes to impaired differentiation, enhanced self-renewal, and proliferation of immature myeloid cells. We demonstrate that ectopic expression of Snai1 in hematopoietic cells predisposes mice to AML development. This effect is mediated by interaction with the histone demethylase KDM1A/LSD1. Our data shed new light on the role of SNAI1 in leukemia development and identify a novel mechanism of LSD1 corruption in cancer. This is particularly pertinent given the current interest surrounding the use of LSD1 inhibitors in the treatment of multiple different malignancies, including AML. Show less
no PDF DOI: 10.1182/blood.2019002548
SNAI1
Josh Lewis Stern, Grace Hibshman, Kevin Hu +6 more · 2020 · Molecular cancer research : MCR · added 2026-04-24
In a substantial fraction of cancers
no PDF DOI: 10.1158/1541-7786.MCR-19-1244
SNAI1
Yuehan Wan, Haichao Liu, Ming Zhang +8 more · 2020 · Head & neck · Wiley · added 2026-04-24
Epithelial-mesenchymal transition (EMT) plays a critical role in cancer progression and is primarily regulated by several EMT-inducing transcription factors (EMT-TFs), including TWIST1, TWIST2, SNAI1, Show more
Epithelial-mesenchymal transition (EMT) plays a critical role in cancer progression and is primarily regulated by several EMT-inducing transcription factors (EMT-TFs), including TWIST1, TWIST2, SNAI1, SNAI2, ZEB1, and ZEB2. However, the prognostic value of EMT-TFs remains controversial in head and neck squamous cell carcinoma (HNSCC). Studies on the prognostic role of EMT-TFs in HNSCC were searched for in the Web of Science, Science Direct, Proquest, EMBASE, PubMed, and Cochrane Library. Meta-analysis was performed by using Revman 5.2 software. The pooled analysis showed that overexpression of EMT-TFs indicated a poor overall survival (OS) (HR = 1.93, 95% CI = 1.67-2.23) of HNSCC. Subgroup analysis for individual EMT-TFs revealed that overexpression of TWIST1 (HR = 1.61, 95% CI = 1.29-2.02), SNAI1 (HR = 2.17, 95% CI = 1.63-2.88), SNAI2 (HR = 1.90, 95% CI = 1.38-2.62), and ZEB1 (HR = 2.70, 95% CI = 1.61-4.53) were significantly associated with poor OS of HNSCC. These findings support the hypothesis that overexpression of EMT-TFs indicates a poor prognosis for HNSCC patients. Show less
no PDF DOI: 10.1002/hed.26104
SNAI1
Jianchao Zhang, Xinxin Lin, Liufeng Wu +4 more · 2020 · Oncogene · Nature · added 2026-04-24
Aurora B is a serine/threonine kinase that has been implicated in regulating cell proliferation in distinct cancers, including breast cancer. Here we show that Aurora B expression is elevated in basal Show more
Aurora B is a serine/threonine kinase that has been implicated in regulating cell proliferation in distinct cancers, including breast cancer. Here we show that Aurora B expression is elevated in basal-like breast cancer (BLBC) compared with other breast cancer subtypes. This high level of expression seems to correlate with poor metastasis-free survival and relapse-free survival in affected patients. Mechanistically, we show that elevated Aurora B expression in breast cancer cells activates AKT/GSK3β to stabilize Snail1 protein, a master regulator of epithelial-mesenchymal transition (EMT), leading to EMT induction in a kinase-dependent manner. Conversely, Aurora B knock down by short-hairpin RNAs (shRNAs) suppresses AKT/GSK3β/Snail1 signaling, reverses EMT and reduces breast cancer metastatic potential in vitro and in vivo. Finally, we identified a specific OCT4 phosphorylation site (T343) responsible for mediating Aurora B-induced AKT/GSK3β/Snail1 signaling and EMT that could be attenuated by Aurora B kinase inhibitor treatment. These findings support that Aurora B induces EMT to promote breast cancer metastasis via OCT4/AKT/GSK3β/Snail1 signaling. Pharmacologic Aurora B inhibition might be a potential effective treatment for breast cancer patients with metastatic disease. Show less
no PDF DOI: 10.1038/s41388-020-1165-z
SNAI1
Shu-Yu Lai, Hong-Mei Guan, Jie Liu +7 more · 2020 · Journal of cellular physiology · Wiley · added 2026-04-24
Recently, long noncoding RNA SNHG12 has been reported to be dysregulated in various types of cancer. This study investigated its biological function and the underlying molecular mechanism in cervical Show more
Recently, long noncoding RNA SNHG12 has been reported to be dysregulated in various types of cancer. This study investigated its biological function and the underlying molecular mechanism in cervical squamous cell carcinoma (CSCC). We found that SNHG12 was significantly overexpressed in CSCC tissues. Further evidence showed that human papillomavirus (HPV) type 16 E6 and E7 might regulate the expression level of SNHG12 by modulating transcription factor c-Myc. Functional experiments suggested that SNHG12 knockdown dramatically repressed CSCC cells proliferation, migration, and invasion while induced apoptosis in vitro as well as suppressed tumor growth in vivo. In addition, SNHG12 could facilitate epithelial-mesenchymal transition through ERK/Slug/E-cadherin pathway at least in part. Our findings highlight SNHG12 functions as an oncogenic long noncoding RNA in malignant phenotype and tumorigenesis of CSCC, which implicate it may be a potential target for CSCC treatment. Show less
no PDF DOI: 10.1002/jcp.29446
SNAI1
Jing Huang, You Qin, Chensu Yang +11 more · 2020 · Aging · Impact Journals · added 2026-04-24
Existing evidence has shown that circulating Epstein-Barr virus (EBV)-miR-BART13-3p is highly expressed in plasma of nasopharyngeal carcinoma (NPC) patients, especially among patients with advanced di Show more
Existing evidence has shown that circulating Epstein-Barr virus (EBV)-miR-BART13-3p is highly expressed in plasma of nasopharyngeal carcinoma (NPC) patients, especially among patients with advanced diseases. However, the exact role that EBV-miR-BART13-3p plays in the development of NPC remains poorly understood. Here we show that up-regulated expression of EBV-miR-BART13-3p leads to increased capacity in migration and invasion of NPC cells Show less
no PDF DOI: 10.18632/aging.102618
SNAI1
Chia-Hao Tung, Li-Wei Kuo, Meng-Fan Huang +6 more · 2020 · Oncogene · Nature · added 2026-04-24
Treatment of ovarian cancer (OvCa) remains challenging owing to its high recurrence rates. Detachment of cancer cells into the peritoneal fluid plays a key role in OvCa relapse, but how this occurs re Show more
Treatment of ovarian cancer (OvCa) remains challenging owing to its high recurrence rates. Detachment of cancer cells into the peritoneal fluid plays a key role in OvCa relapse, but how this occurs remains incompletely understood. Here we examined global miRNA expression profiles of paired primary/recurrent OvCa specimens and identified a novel biomarker, microRNA-150-5p (miR-150-5p), that was significantly upregulated in 16 recurrent OvCa tissues compared with their matched primary specimens. Analyses of cohorts from two other groups confirmed that expression of miR-150-5p was associated with early relapse and poor survival of OvCa patients. Inhibition of miR-150-5p significantly inhibited the migration and invasion of OvCa cells and induced a mesenchymal-epithelial transition (MET) phenotype. We demonstrated that the proto-oncogene, MYB, is an miR-150-5p target in OvCa cells and that the miR-150-5p/c-Myb/Slug axis plays important roles in regulating epithelial-mesenchymal transition (EMT) in OvCa cells. Expression of MYB was significantly correlated with good clinical outcome in OvCa and was negatively correlated with Slug expression in late-stage clinical specimens. These results suggest that miR-150-5p upregulation mediates the progression of recurrent OvCa by targeting the c-Myb/Slug pathway. Inhibition of miR-150-5p may serve as a new therapeutic strategy for preventing recurrence of OvCa. Show less
no PDF DOI: 10.1038/s41388-019-1025-x
SNAI1
Jun Liu, Zhengsheng Wu, Dan Han +16 more · 2020 · Hepatology (Baltimore, Md.) · Wiley · added 2026-04-24
Endoplasmic reticulum (ER) stress is associated with liver inflammation and hepatocellular carcinoma (HCC). However, how ER stress links inflammation and HCC remains obscure. Mesencephalic astrocyte-d Show more
Endoplasmic reticulum (ER) stress is associated with liver inflammation and hepatocellular carcinoma (HCC). However, how ER stress links inflammation and HCC remains obscure. Mesencephalic astrocyte-derived neurotrophic factor (MANF) is an ER stress-inducible secretion protein that inhibits inflammation by interacting with the key subunit of nuclear factor kappa light chain enhancer of activated B cells (NF-κB) p65. We hypothesized that MANF may play a key role in linking ER stress and inflammation in HCC. Here, we found that MANF mRNA and protein levels were lower in HCC tissues versus adjacent noncancer tissues. Patients with high levels of MANF had better relapse-free survival and overall survival rates than those with low levels. MANF levels were also associated with the status of liver cirrhosis, advanced tumor-node-metastasis (TNM) stage, and tumor size. In vitro experiments revealed that MANF suppressed the migration and invasion of hepatoma cells. Hepatocyte-specific deletion of MANF accelerated N-nitrosodiethylamine (DEN)-induced HCC by up-regulating Snail1+2 levels and promoting epithelial-mesenchymal transition (EMT). MANF appeared in the nuclei and was colocalized with p65 in HCC tissues and in tumor necrosis factor alpha (TNF-α)-treated hepatoma cells. The interaction of p65 and MANF was also confirmed by coimmunoprecipitation experiments. Consistently, knockdown of MANF up-regulated NF-κB downstream target genes TNF-α, interleukin (IL)-6 and IL-1α expression in vitro and in vivo. Finally, small ubiquitin-related modifier 1 (SUMO1) promoted MANF nuclear translocation and enhanced the interaction of MANF and p65. Mutation of p65 motifs for SUMOylation abolished the interaction of p65 and MANF. MANF plays an important role in linking ER stress and liver inflammation by inhibiting the NF-κB/Snail signal pathway in EMT and HCC progression. Therefore, MANF may be a cancer suppressor and a potential therapeutic target for HCC. Show less
no PDF DOI: 10.1002/hep.30917
SNAI1
Hua-Zhi Ling, Shu-Zhen Xu, Rui-Xue Leng +8 more · 2020 · Rheumatology (Oxford, England) · Oxford University Press · added 2026-04-24
Clinical diagnosis of SLE is currently challenging due to its heterogeneity. Many autoantibodies are associated with SLE and are considered potential diagnostic markers, but systematic screening and v Show more
Clinical diagnosis of SLE is currently challenging due to its heterogeneity. Many autoantibodies are associated with SLE and are considered potential diagnostic markers, but systematic screening and validation of such autoantibodies is lacking. This study aimed to systematically discover new autoantibodies that may be good biomarkers for use in SLE diagnosis. Sera from 15 SLE patients and 5 healthy volunteers were analysed using human proteome microarrays to identify candidate SLE-related autoantibodies. The results were validated by screening of sera from 107 SLE patients, 94 healthy volunteers and 60 disease controls using focussed arrays comprised of autoantigens corresponding to the identified candidate antibodies. Logistic regression was used to derive and validate autoantibody panels that can discriminate SLE disease. Extensive ELISA screening of sera from 294 SLE patients and 461 controls was performed to validate one of the newly discovered autoantibodies. A total of 31, 11 and 18 autoantibodies were identified to be expressed at significantly higher levels in the SLE group than in the healthy volunteers, disease controls and healthy volunteers plus disease control groups, respectively, with 25, 7 and 13 of these differentially expressed autoantibodies being previously unreported. Diagnostic panels comprising anti-RPLP2, anti-SNRPC and anti-PARP1, and anti-RPLP2, anti-PARP1, anti-MAK16 and anti- RPL7A were selected. Performance of the newly discovered anti-MAK16 autoantibody was confirmed by ELISA. Some associations were seen with clinical characteristics of SLE patients, such as disease activity with the level of anti-PARP1 and rash with the level of anti-RPLP2, anti-MAK16 and anti- RPL7A. The combined autoantibody panels identified here show promise for the diagnosis of SLE and for differential diagnosis of other major rheumatic immune diseases. Show less
no PDF DOI: 10.1093/rheumatology/kez634
SNRPC
Quan Chen, Peng Gao, Yongxi Song +5 more · 2020 · Cancer medicine · Wiley · added 2026-04-24
It is critical to identify patients with stage II and III colorectal cancer (CRC) who will benefit from adjuvant chemotherapy (ACT) after curative surgery, while the only use of clinical factors is in Show more
It is critical to identify patients with stage II and III colorectal cancer (CRC) who will benefit from adjuvant chemotherapy (ACT) after curative surgery, while the only use of clinical factors is insufficient to predict this beneficial effect. In this study, we performed genetic algorithm (GA) to select ACT candidate genes, and built a predictive model of support vector machine (SVM) using gene expression profiles from the Gene Expression Omnibus database. The model contained four ACT candidate genes (EDEM1, MVD, SEMA5B, and WWP2) and TNM stage (stage II or III). After using Subpopulation Treatment Effect Pattern Plot to determine the optimal cutoff value of predictive scores, the validated patients from The Cancer Genome Atlas database can be divided into the predictive ACT-benefit/-futile groups. Patients in the predictive ACT-benefit group with 5-fluorouracil (5-Fu)-based ACT had significantly longer relapse-free survival (RFS) compared to those without ACT (P = .015); However, the difference in RFS in the predictive ACT-futile group was insignificant (P = .596). The multivariable analysis found that the predictive groups were significantly associated with the effect of ACT (P Show less
no PDF DOI: 10.1002/cam4.2952
WWP2
Mao-Xu Ge, Hong-Tao Liu, Na Zhang +7 more · 2020 · British journal of pharmacology · Blackwell Publishing · added 2026-04-24
This study investigates the antifibrotic activities and potential mechanisms of costunolide (COS), a natural sesquiterpene compound. Rats subjected to bile duct ligation and mice challenged with CCl I Show more
This study investigates the antifibrotic activities and potential mechanisms of costunolide (COS), a natural sesquiterpene compound. Rats subjected to bile duct ligation and mice challenged with CCl In animals, COS administration attenuated hepatic histopathological injury and collagen accumulation and reduced the expression of fibrogenic genes. COS time- and dose-dependently suppressed the levels of fibrotic markers in LX-2 cells and mouse pHSCs. Mechanistic studies showed COS destabilized Notch3 and subsequently inhibited the Notch3-HES1 pathway, thus inhibiting HSC activation. Furthermore, COS blocked the WW domain-containing protein 2 (WWP2)/protein phosphatase 1G (PPM1G) interaction and enhanced the effect of WWP2 on Notch3 degradation. COS exerted potent antifibrotic effects in vitro and in vivo by disrupting the WWP2/PPM1G complex, promoting Notch3 degradation and inhibiting the Notch3/HES1 pathway. This indicates that COS may be a potential therapeutic candidate for the treatment of liver fibrosis. Show less
no PDF DOI: 10.1111/bph.14873
WWP2
Binbin Wang, Pinghua Li, Wuduo Zhou +8 more · 2019 · Animals : an open access journal from MDPI · MDPI · added 2026-04-24
The present study aimed to identify the molecular markers for genes that influence intramuscular fat content (IFC), but not average backfat thickness (ABT). A total of 330 Suhuai pigs were slaughtered Show more
The present study aimed to identify the molecular markers for genes that influence intramuscular fat content (IFC), but not average backfat thickness (ABT). A total of 330 Suhuai pigs were slaughtered, and measurements of IFC and ABT were obtained. Phenotypic and genetic correlations between IFC and ABT were calculated. Thirteen single nucleotide polymorphisms (SNPs) among 12 candidate genes for IFC were analyzed, including Show less
📄 PDF DOI: 10.3390/ani9110858
MC4R
Haiyang Hao, Rutao Lin, Zhiyuan Li +5 more · 2019 · Biochemical and biophysical research communications · Elsevier · added 2026-04-24
Melanocortin 4 receptor (MC4R)-deficient mice had been used for several years to study human nonalcoholic steatohepatitis (NASH). However, although liver pathologic and biochemical indicators have bee Show more
Melanocortin 4 receptor (MC4R)-deficient mice had been used for several years to study human nonalcoholic steatohepatitis (NASH). However, although liver pathologic and biochemical indicators have been examined, mice models do not always faithfully display the phenotype of the human disease. In this study, we investigated the MC4R knockout phenotype in miniature pigs. We found that pigs lacking MC4R exhibited hyperorexia, insulin resistance, hyperinsulinemia, disordered lipid metabolism and their livers accumulated significant amounts of fat. We have shown that deletion of MC4R results in hyperphagia and increased body fat, ultimately leading to hepatic steatosis without atherogenic diet. Show less
no PDF DOI: 10.1016/j.bbrc.2019.08.016
MC4R
Xiaojiao Xu, Xiaoling Chen, Zhiqing Huang +6 more · 2019 · Food & function · Royal Society of Chemistry · added 2026-04-24
Phloretin, abundantly present in apples, pears and other fruits, has been found to have antioxidant, immunosuppressive and anti-inflammatory activities. It has been reported that oral administration o Show more
Phloretin, abundantly present in apples, pears and other fruits, has been found to have antioxidant, immunosuppressive and anti-inflammatory activities. It has been reported that oral administration of phloretin dose-dependently increased feed intake in mice, but the mechanism is unclear yet. The aim of this study was to investigate the effect of dietary phloretin supplementation on the feed intake in C57BL/6J mice and to identify its mechanism. Here, sixty C57BL/6J mice (28-day age) were randomly chosen for four dietary treatments and fed a basal diet or a basal diet supplemented with 0.1%, 0.2%, and 0.3% phloretin, respectively, in a 6-week trial. We showed that mice in the 0.1%, 0.2%, and 0.3% phloretin-supplemented groups had increased accumulative feed intake compared with the control group. Furthermore, dietary phloretin supplementation significantly increased the ghrelin mRNA level in the stomach and hypothalamus, and decreased the cholecystokinin (CCK) mRNA level in the duodenum in a dose-dependent manner. The mRNA levels of neuropeptide Y (NPY), agouti-related protein (AgRP), pro-opiomelanocortin and melanocortin receptors 4 (MC4R), and pro-opiomelanocortin (POMC) in the hypothalamus were altered in response to dietary phloretin supplementation. Moreover, we confirmed that dietary phloretin supplementation reduced the expressions of miR-488 and miR-103, two feed intake-related miRNAs. Our present study provides evidence that dietary phloretin supplementation could increase feed intake in mice, which might be attributed to the stimulation of the hypothalamic feeding center via ghrelin, miRNAs (miR-103 and miR-488) and feeding signal factor-related genes (NPY, AgRP, MC4R and POMC), and to the inhibition of CCK to increase gastric emptying. Show less
no PDF DOI: 10.1039/c9fo00815b
MC4R
Liyuan Lv, Xu-Fang Liang, Kang Huang +1 more · 2019 · Fish physiology and biochemistry · Springer · added 2026-04-24
Agmatine, an endogenous biogenic amine, is considered to be a central neurotransmitter. And it plays an important role in mammal feeding behavior. However, there were few studies on the effect of agma Show more
Agmatine, an endogenous biogenic amine, is considered to be a central neurotransmitter. And it plays an important role in mammal feeding behavior. However, there were few studies on the effect of agmatine on feeding behavior in fishes. Here, we investigated the impact of intracerebroventricular (ICV) injections of agmatine (1.25-20 nmol/fish) on food intake in mandarin fish (Siniperca chuatsi). At 1-h post-injection, food intake showed a significant decrease in agmatine-treated fishes compared with the saline treated. Furthermore, the food intake in agmatine treatment mostly did not differ from that in saline treatment at 4--24-h post-injection as well as the results of genes expression of neuropeptide Y (NPY), agouti-regulated peptide (AgRP), and anorexigenic melanocortin 4 receptor (MC4R). In accordance with the insulin level increasing in liver, the gene expression of insulin receptor substrate (IRS2) was significantly higher in agmatine treatment compared to saline treatment at 1-h post-injection. Thus, the anorexigenic effect of agmatine is likely to decrease NPY and AgRP expression levels and increase MC4R and IRS2 levels which was coupled with stimulation of insulin secretion. Although these initial findings are limited in dose, the data firstly provides evidence for the anorectic effects of agmatine in fish. Show less
no PDF DOI: 10.1007/s10695-019-00659-w
MC4R

The MC

Shengpan Chen, Yuchun Zuo, Lei Huang +11 more · 2019 · British journal of pharmacology · Blackwell Publishing · added 2026-04-24
Inflammasome-mediated pyroptosis is an important neuronal cell death mechanism. Previous studies reported that activation of melanocortin MC One hundred and sixty-nine male CD1 mice were used. ICH was Show more
Inflammasome-mediated pyroptosis is an important neuronal cell death mechanism. Previous studies reported that activation of melanocortin MC One hundred and sixty-nine male CD1 mice were used. ICH was induced by injection of bacterial collagenase into the right-side basal ganglia. RO27-3225, a selective agonist of MC Expression of MC RO27-3225 suppressed NLRP1-dependent neuronal pyroptosis and improved neurological function, possibly mediated by activation of MC Show less
no PDF DOI: 10.1111/bph.14639
MC4R
Lei Wang, Jian Cheng, Zhen Hua +5 more · 2019 · European journal of pharmacology · Elsevier · added 2026-04-24
α-melanocyte stimulating hormone (α-MSH) is a member of the melanocortin family, that has displayed important biological functions in diverse cells and tissues. The purpose of this study is to test th Show more
α-melanocyte stimulating hormone (α-MSH) is a member of the melanocortin family, that has displayed important biological functions in diverse cells and tissues. The purpose of this study is to test the effect of α-MSH on the differentiation and mineralization of osteoblast cells. The expression of the α-MSH membrane receptor MC1R but not MC2R, MC3R, or MC4R increased distinctively during the osteogenic differentiation from 3, 7 to 14 d. Treatment with α-MSH promoted the differentiation and mineralization of MC3T3-E1 cells by increasing the activity of ALP, enhancing Alizarin Red S staining, and stimulating the expression of osteogenic genes, including ALP1, osteocalcin (Bglap2), and osterix (Sp7). Importantly, we found that α-MSH increased the expression of Runx-2, a master transcriptional factor of osteogenic differentiation. Mechanically, we found that the activation of ERK1/2 was involved in this process. Using the small interfering (si) RNA knockdown experiment, we proved that the effects of α-MSH on differentiation and mineralization of osteoblast cells are mediated by MC1R. The present study proposes α-MSH as a potential therapeutic agent to stimulate bone formation for osteoporosis and bone defect. Meanwhile, MC1R could also be a target candidate for the treatment of bone metabolism diseases. Show less
no PDF DOI: 10.1016/j.ejphar.2018.11.033
MC4R
Elizabeth T Cirulli, Lining Guo, Christine Leon Swisher +9 more · 2019 · Cell metabolism · Elsevier · added 2026-04-24
Obesity is a heterogeneous phenotype that is crudely measured by body mass index (BMI). There is a need for a more precise yet portable method of phenotyping and categorizing risk in large numbers of Show more
Obesity is a heterogeneous phenotype that is crudely measured by body mass index (BMI). There is a need for a more precise yet portable method of phenotyping and categorizing risk in large numbers of people with obesity to advance clinical care and drug development. Here, we used non-targeted metabolomics and whole-genome sequencing to identify metabolic and genetic signatures of obesity. We find that obesity results in profound perturbation of the metabolome; nearly a third of the assayed metabolites associated with changes in BMI. A metabolome signature identifies the healthy obese and lean individuals with abnormal metabolomes-these groups differ in health outcomes and underlying genetic risk. Specifically, an abnormal metabolome associated with a 2- to 5-fold increase in cardiovascular events when comparing individuals who were matched for BMI but had opposing metabolome signatures. Because metabolome profiling identifies clinically meaningful heterogeneity in obesity, this approach could help select patients for clinical trials. Show less
📄 PDF DOI: 10.1016/j.cmet.2018.09.022
MC4R
Tsung-Wei Huang, Sheng-Tien Li, Duan-Yu Chen +1 more · 2019 · Neuropeptides · Elsevier · added 2026-04-24
Olfactory dysfunction significantly impedes the life quality of patients. Neuropeptide Y (NPY) is not only a neurotrophic factor in the rodent olfactory system but also an orexigenic peptide that regu Show more
Olfactory dysfunction significantly impedes the life quality of patients. Neuropeptide Y (NPY) is not only a neurotrophic factor in the rodent olfactory system but also an orexigenic peptide that regulates feeding behavior. NPY increases the olfactory receptor neurons (ORNs) responsivity during starvation; however, whether NPY can promote differentiation of human ORNs remains unexplored. This study investigates the effect of NPY on the differentiation of human olfactory neuroepithelial cells in vitro. Human olfactory neuroepithelium explants were cultured on tissue culture polystyrene dishes for 21 days. Then, cells were cultured with or without NPY at the concentration of 0.5 ng/mℓ for 7 days. The effects of treatment were assessed by phase contrast microscopy, immunocytochemistry and western blot analysis. The further mechanism was evaluated with NPY Y1 receptor-selected antagonist BIBP3226. NPY-treated olfactory neuroepithelial cells exhibited thin bipolar shape, low circularity, low spread area, and long processes. The expression levels of Ascl1, βIII tubulin, GAP43 and OMP were significantly higher in NPY-treated cells than in controls (p < 0.05). NPY-treated olfactory neuroepithelial cells expressed more components of signal transduction apparatuses, G Show less
no PDF DOI: 10.1016/j.npep.2019.101964
ADCY3
Ming Zhang, Yonglin Zhao, Junjie Zhao +2 more · 2019 · BMC neurology · BioMed Central · added 2026-04-24
Glioma is the most common primary malignant brain tumor with high mortality and poor prognosis. Our aim was to clarify the correlation between Kinase-anchored protein 6 (AKAP6) gene polymorphisms and Show more
Glioma is the most common primary malignant brain tumor with high mortality and poor prognosis. Our aim was to clarify the correlation between Kinase-anchored protein 6 (AKAP6) gene polymorphisms and glioma susceptibility and prognosis in Chinese Han population. Five single-nucleotide polymorphisms (SNPs) of AKAP6 were genotyped by Agena MassARRAY in 575 glioma patients and 500 healthy controls. Logistic regression model was utilized to calculate odds ratios (OR) and 95% confidence intervals (CI). The associations between polymorphisms and survival were assessed using the log-rank test, Kaplan-Meier analysis and Cox regression model. We found that rs2239647 polymorphism was strongly associated with an increased risk of glioma (OR = 1.90, p = 0.007) and a worse prognosis for glioma, especially in high-grade glioma (HR = 1.67, p = 0.034). Stratified analysis showed that rs2239647 increased the risk of glioma in female (OR = 1.62, p = 0.016). Whereas, rs4261436 (HR = 0.70, p = 0.045) and rs17522122 (HR = 0.75, p = 0.016) were associated with better prognosis of astrocytoma. In addition, we also found that surgical methods and chemotherapy are critical factors for the prognosis of glioma patients. This study firstly provided evidence for the impact of AKAP6 polymorphisms on susceptibility and prognosis of glioma, suggesting AKAP6 variants might have potential roles in the etiology of glioma. Show less
📄 PDF DOI: 10.1186/s12883-019-1504-2
AKAP6
Jie Gao, Gangqiang Ding, Qi Li +3 more · 2019 · Food research international (Ottawa, Ont.) · Elsevier · added 2026-04-24
The role of Tibet kefir milk (TKM) feeding on fat deposition was investigated in high-fat diet (HFD)-fed human flora-associated (HFA) rats. TKM feeding reduced abdominal fat mass from 33.9 g to 24.0 g Show more
The role of Tibet kefir milk (TKM) feeding on fat deposition was investigated in high-fat diet (HFD)-fed human flora-associated (HFA) rats. TKM feeding reduced abdominal fat mass from 33.9 g to 24.0 g and serum triglyceride (TG) from 0.75 mmol/L to 0.47 mmol/L, and caused lipoprotein lipase (LPL) to decrease from 395.8 ± 36.0 ng/L to 362.3 ± 64.4 ng/L in fat and increase from 287.3 ± 40.8 ng/L to 329.8 ± 48.5 ng/L and 312.5 ± 22.0 to 375.1 ± 30.8 ng/L in liver and serum, respectively. Likewise, TMK feeding down-regulated Lpl gene expression in fat and Angptl4 (angiopoietin-like protein-4, also known as fasting-induced adipose factor) gene expression in liver, and up-regulated Angptl4 gene expression in fat. Sequence analysis showed that the Firmicutes/Bacteroidetes proportion and Verrucomicrobia at the phylum level, Akkermansia, Escherichia and Oscillospira at the genus level, as well as Escherichia coli at the species level were positively regulated by TKM. The results indicated that TKM decreased abdominal fat deposition and serum TG by regulating Lpl and Angptl4 at the transcriptional level. The microbiota groups mentioned above were regulated by TKM at the same time and may be the potential intervention targets to reduce fat deposition. Show less
no PDF DOI: 10.1016/j.foodres.2019.03.029
ANGPTL4
Ting Zou, Shan Jiang, Waruna Lakmal Dissanayaka +5 more · 2019 · Journal of cellular biochemistry · Wiley · added 2026-04-24
Inducing of dental pulp stem cells (DPSCs) into endothelial cells (ECs) to prevascularize pulp tissue constructs may offer a novel and viable approach for enhancing pulp regeneration. However, there a Show more
Inducing of dental pulp stem cells (DPSCs) into endothelial cells (ECs) to prevascularize pulp tissue constructs may offer a novel and viable approach for enhancing pulp regeneration. However, there are numerous challenges in current methods for the acquisition of sufficient translational ECs. It was known that Sema4D/PlexinB1 signaling exerts profound effects on enhancing vascular endothelial growth factor (VEGF) secretion and angiogenesis. Whether Sema4D/PlexinB1 could regulate endothelial differentiation of DPSCs is not yet investigated. In this study, when DPSCs were treated with Sema4D (2 μg/mL), ECs-specific (VEGFR1, VEGFR2, CD31, and vWF), and angiogenic genes and proteins were significantly upregulated. The induced ECs exhibited similar endothelial vessel formation ability to that of human umbilical vein endothelial cells (HUVECs). Furthermore, phosphorylation of AKT increased dramatically within 5 minutes (from 0.93 to 21.8), while p-ERK1/2 was moderately elevated (from 0.94 to 2.65). In summary, our results demonstrated that Sema4D/PlexinB1 signaling induces endothelial differentiation of DPSCs. The interactions of Sema4D, VEGF, ANGPTL4, ANG1, and HIF-1α may play a crucial role in mediating the differentiation process. Show less
no PDF DOI: 10.1002/jcb.28635
ANGPTL4
Yu Sun, Yi Li, Chen Liu +6 more · 2019 · Bioscience reports · added 2026-04-24
Angiopoietin-like protein 4 (ANGPTL4) is a multifunctional secreted protein that can be induced by fasting, hypoxia and glucocorticoids. ANGPTL4 has been associated with a variety of diseases; however Show more
Angiopoietin-like protein 4 (ANGPTL4) is a multifunctional secreted protein that can be induced by fasting, hypoxia and glucocorticoids. ANGPTL4 has been associated with a variety of diseases; however, the role of ANGPTL4 in cardiac hypertrophy remains poorly understood. In our study, we aimed to explore the effect of ANGPTL4 on phenylephrine-induced cardiomyocyte hypertrophy. Our results showed that knockdown of ANGPTL4 expression significantly exacerbated cardiomyocyte hypertrophy, as demonstrated by increased hypertrophic marker expression, including ANP and cell surface area. Moreover, significantly reduced fatty acid oxidation, as featured by decreased CPT-1 levels, was observed in hypertrophic cardiomyocytes following ANGPTL4 down-regulation. Furthermore, knockdown of ANGPLT4 led to down-regulated expression of peroxisome proliferator-activated receptor α (PPARα), which is the key regulator of cardiac fatty acid oxidation. In addition, ANGPTL4 silencing promoted the activation of JNK1/2, and JNK1/2 signaling blockade could restore the level of PPARα and significantly ameliorate the ANGPTL4 knockdown-induced cardiomyocyte hypertrophy. Therefore, our study demonstrated that ANGPTL4 regulates PPARα through JNK1/2 signaling and is required for the inhibition of cardiomyocyte hypertrophy. Show less
📄 PDF DOI: 10.1042/BSR20171358
ANGPTL4
Xiangkun Wang, Yizhen Gong, Teng Deng +12 more · 2019 · Journal of cellular biochemistry · Wiley · added 2026-04-24
Hepatocellular carcinoma (HCC) is among the most common and lethal malignancies worldwide. Apolipoproteins (APOs) have been reported increasingly for their relationships with tumors. We aim at explori Show more
Hepatocellular carcinoma (HCC) is among the most common and lethal malignancies worldwide. Apolipoproteins (APOs) have been reported increasingly for their relationships with tumors. We aim at exploring the potential relationships of apolipoprotein A (APOA) and apolipoprotein C (APOC) family members with HCC. A data set, containing 212 hepatitis B virus-related HCC patients, was used for analysis. The diagnostic and prognostic ability of APOA and APOC family genes was figured out. Risk score models and nomograms were developed for the HCC prognosis prediction. Moreover, molecular mechanism exploration were identified biological processes and metabolic pathways of these genes involved in. Validation analysis was carried out using online website. APOA1, APOC1, APOC3, and APOC4 showed robust diagnosis significance (all P < 0.05). APOA4, APOC3, and APOC4 were associated with the overall survival (OS) while APOA4 and APOC4 were linked to recurrence-free survival (RFS, all P ≤ 0.05). Risk score models and nomograms had the advantage of predicting OS and RFS for HCC. Molecular mechanism exploration indicated that these genes were involved in the steroid metabolic process, the PPAR signaling pathway, and fatty acid metabolism. Besides that, validation analysis revealed that APOC1 and APOC4 had an association with OS; and APOC3 was associated with OS and RFS (all P ≤ 0.05). APOA1, APOC1, APOC3, and APOC4 are likely to be potential diagnostic biomarkers and APOC3 and APOC4 are likely to be potential prognostic biomarkers for hepatitis B virus-related HCC. They may be involved in the steroid metabolic process, PPAR signaling pathway, and fatty acid metabolism. Show less
no PDF DOI: 10.1002/jcb.29131
APOA4
Yue Zheng, Yunwang Zhao, Ya Di +5 more · 2019 · RSC advances · Royal Society of Chemistry · added 2026-04-24
Gastric cancer is still among the leading causes of cancer deaths worldwide. Despite the improvements in diagnostic methods, the status of early detection has not been achieved so far. Early diagnosis Show more
Gastric cancer is still among the leading causes of cancer deaths worldwide. Despite the improvements in diagnostic methods, the status of early detection has not been achieved so far. Early diagnosis of gastric cancer may significantly improve the cure rate of patients. Therefore, a new diagnostic method is needed. In this study, subtractive SELEX was performed to screen gastric cancer serum-specific DNA aptamers by using gastric cancer serum and normal serum as the target and negative serum, respectively. Four highly specific aptamers generated for gastric cancer serum, Seq-3, Seq-6, Seq-19 and Seq-54, were developed using whole-serum subtractive SELEX technology with Show less
📄 PDF DOI: 10.1039/c8ra08642g
APOA4
Xiao-Fei Xie, Hong-Juan Chu, Yu-Fen Xu +5 more · 2019 · Cardiology journal · added 2026-04-24
To study the protein profile of the serum exosomes of patients with coronary artery aneurysms (CAA) caused by Kawasaki disease (KD). Two-dimensional electrophoresis (2-DE) was used to identify protein Show more
To study the protein profile of the serum exosomes of patients with coronary artery aneurysms (CAA) caused by Kawasaki disease (KD). Two-dimensional electrophoresis (2-DE) was used to identify proteins from the exosomes of serum obtained from children with CAA caused by KD, as well as healthy controls. Differentially expressed proteins were identified using matrix-assisted laser desorption/ionization time-of-flight/timeof-flight mass spectrometry (MALDI-TOF/TOF MS) analysis. Thirty two differentially expressed proteins were identified (18 up-regulated and 14 downregulated) from serum exosomes of children with CAA and were compared to healthy controls. The expression levels of 4 proteins (TN, RBP4, LRG1, and APOA4) were validated using Western blotting. Classification analysis and protein-protein network analysis showed that they are associated with multiple functional groups, including host immune response, inflammation, apoptotic process, developmental process, and biological adhesion process. These findings establish a comprehensive proteomic profile of serum exosomes from children with CAA caused by KD, and provide additional insights into the mechanisms of CAA caused by KD. Show less
📄 PDF DOI: 10.5603/CJ.a2018.0032
APOA4